TY - JOUR
T1 - Cancer cells educate natural killer cells to a metastasis-promoting cell state
AU - Chan, Isaac S.
AU - Kn utsdóttir, Hildur
AU - Ramakrishnan, Gayathri
AU - Padmanaban, Veena
AU - Warrier, Manisha
AU - Ramirez, Juan Carlos
AU - Dunworth, Matthew
AU - Zhang, Hao
AU - Jaffee, Elizabeth M.
AU - Bader, Joel S.
AU - Ewald, Andrew Josef
N1 - Funding Information:
E.M. Jaffee receives grant funding from AduroBiotech, Bristol Myers Squibb, and Amgen and serves on advisory boards for CSTONE, Adaptive Biotech, DragonFly, and Genocea. Through a licensing agreement between JHU and AduroBiotech, both JHU and E.M. Jaffee have the potential to receive royalty payments in the future. J.S. Bader is a founder and director of Neo-chromosome and a member of the scientific advisory board of AI Therapeutics. A.J. Ewald’s spouse is an employee of ImmunoCore. A.J. Ewald and V. Padmanaban are listed as inventors on a patent application related to the use of antibodies as cancer therapeutics. A.J. Ewald is an inventor of a patent related to the use of K14 as a prognostic indicator for breast cancer outcomes.
Funding Information:
A.J. Ewald received support for this project through grants from the Breast Cancer Research Foundation/Pink Agenda (BCRF-19-048), Twisted Pink, Hope Scarves, and the National Institutes of Health/National Cancer Institute (U01CA217846, U54CA2101732, 3P30CA006973). J.S. Bader received support for this project through a grant from the National Institutes of Health/National Cancer Institute (U01CA217846). I.S. Chan received support from National Institutes of Health/National Cancer Institute (T32CA009071) and the Conquer Cancer Foundation Young Investigator Award. Both A.J. Ewald and J.S. Bader received support from the Jayne Koskinas Ted Giovanis Foundation for Health and Policy and the Breast Cancer Research Foundation, private foundations committed to critical funding of cancer research. The opinions, findings, conclusions, or recommendations expressed in this material are those of the authors and not necessarily those of the Jayne Koskinas Ted Giovanis Foundation for Health and Policy or the Breast Cancer Research Foundation, or their respective directors, officers, or staffs.
Publisher Copyright:
© 2020 Chan et al.
PY - 2020/9/7
Y1 - 2020/9/7
N2 - Natural killer (NK) cells have potent antitumor and antimetastatic activity. It is incompletely understood how cancer cells escape NK cell surveillance. Using ex vivo and in vivo models of metastasis, we establish that keratin-14+ breast cancer cells are vulnerable to NK cells. We then discovered that exposure to cancer cells causes NK cells to lose their cytotoxic ability and promote metastatic outgrowth. Gene expression comparisons revealed that healthy NK cells have an active NK cell molecular phenotype, whereas tumor-exposed (teNK) cells resemble resting NK cells. Receptor ligand analysis between teNK cells and tumor cells revealed multiple potential targets. We next showed that treatment with antibodies targeting TIGIT, antibodies targeting KLRG1, or small-molecule inhibitors of DNA methyltransferases (DMNT) each reduced colony formation. Combinations of DNMT inhibitors with anti-TIGIT or anti-KLRG1 antibodies further reduced metastatic potential. We propose that NK-directed therapies targeting these pathways would be effective in the adjuvant setting to prevent metastatic recurrence.
AB - Natural killer (NK) cells have potent antitumor and antimetastatic activity. It is incompletely understood how cancer cells escape NK cell surveillance. Using ex vivo and in vivo models of metastasis, we establish that keratin-14+ breast cancer cells are vulnerable to NK cells. We then discovered that exposure to cancer cells causes NK cells to lose their cytotoxic ability and promote metastatic outgrowth. Gene expression comparisons revealed that healthy NK cells have an active NK cell molecular phenotype, whereas tumor-exposed (teNK) cells resemble resting NK cells. Receptor ligand analysis between teNK cells and tumor cells revealed multiple potential targets. We next showed that treatment with antibodies targeting TIGIT, antibodies targeting KLRG1, or small-molecule inhibitors of DNA methyltransferases (DMNT) each reduced colony formation. Combinations of DNMT inhibitors with anti-TIGIT or anti-KLRG1 antibodies further reduced metastatic potential. We propose that NK-directed therapies targeting these pathways would be effective in the adjuvant setting to prevent metastatic recurrence.
UR - http://www.scopus.com/inward/record.url?scp=85087800958&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087800958&partnerID=8YFLogxK
U2 - 10.1083/jcb.202002077
DO - 10.1083/jcb.202002077
M3 - Article
C2 - 32645139
AN - SCOPUS:85087800958
SN - 0021-9525
VL - 219
JO - Journal of Cell Biology
JF - Journal of Cell Biology
IS - 9
M1 - jcb.202002077
ER -